TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00815776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clayton Intra-aural Device (CID)
Description: The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Splint
Description: Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
Study: NCT00176878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10\^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10\^9/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: fludarabine 175 mg/m\^2 (total) on Days -6 through -3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Dose 500 cGy radiation therapy to specific areas of the body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
Study: NCT03327363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback using ICT based monitoring system
Description: In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Feedback using ICT based monitoring system
Description: In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
Study: NCT04259034

Intervention type: OTHER
Intervention: diagnosis of periodontitis in oral lichen planus patients
Description: diagnosis of periodontitis in oral lichen planus patients

Intervention type: OTHER
Intervention: diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
Description: diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
Study: NCT01789710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
Study: NCT02785666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grazoprevir/elbasvir, ribavirin
Description: To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention
Description: To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
Study: NCT02236650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Stepping Stones Triple P (PC-SS Triple P)
Description: PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual for 4 weeks
Study: NCT01964287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMBRAX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Study: NCT02200068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SANOIA Website
Study: NCT00809510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 20 mg ABT-089 taken once-daily for 6 months
Study: NCT02353403

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar
Description: A 210g chocolate dairy dessert made with 35g of dextrose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOS
Description: A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
Study: NCT00481988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iomed phoresor transcranial direct current stimulation
Description: for the sham group the current is turned off after 10 seconds
Study: NCT02264652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Transcranial Direct Stimulation
Description: Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
Study: NCT03216395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-scope Clips
Description: Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemo-clipping
Description: Hemo-clipping \<=20 clips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermo-coagulation
Description: contact thermo-coagulation \< = 8 pulses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
Study: NCT03228992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 4 doses of placebo over a 24 hour period.
Study: NCT03216668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TONKA
Description: Administered orally twice a day, 2 tablets each time, for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEGALON
Description: Administered orally three times a day, two tablets each time, for 6 weeks
Study: NCT02616536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching methods
Description: the two teaching methods will be given to two groups of students and their knowledge gain will be analysed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching methods
Description: the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
Study: NCT01938560

Intervention type: OTHER
Intervention: Survey Responses
Description: Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.

Intervention type: OTHER
Intervention: Survey Responses
Description: Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
Study: NCT01046968

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lepticore
Description: 300 mg twice daily
Study: NCT03793413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual frenotomy
Description: A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
Study: NCT02078232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: puncture of head of pancreas
Description: puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: puncture of head of pancreas
Description: puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle
Study: NCT01939691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Description: Difluprednate 0.05% - corticosteroid eyedrop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Description: Difluprednate 0.05% - corticosteroid eyedrop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac
Description: Nepafenac 0.1% - NSAID eyedrop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac
Description: Nepafenac 0.1% - NSAID eyedrop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: prednisolone acetate 1% - corticosteroid eyedrop
Study: NCT03392038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thin ADM
Description: Use of soft tissue allograft for root coverage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thick ADM
Description: Periodontal surgical procedure to coronally position the tissue over the ADM allograft
Study: NCT01032668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: high dose clopidogrel continuing after percutaneous coronary intervention
Study: NCT00366249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: 150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
Study: NCT00829036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wayfinding Prototype
Description: A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
Study: NCT02460549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic education program
Study: NCT03428295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dose Safety AP system
Description: Device will be used to automatically dose insulin
Study: NCT01525420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Therapy (ACT)
Description: ACT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT
Study: NCT00964249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Long acting Beta 2 agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03049930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
Study: NCT01804842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met DR
Description: metformin delayed-release tablets
Study: NCT01425307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
Study: NCT01791465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release exenatide
Description: Single arm study - 2mg Bydureon every 7 days x 16 weeks
Study: NCT03935490

Intervention type: PROCEDURE
Intervention: emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)
Description: The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary.
Study: NCT02373566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novomaix dermal substitute in combination with STSG
Description: Novomaix dermal substitute in combination with STSG
Study: NCT04530968

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02078089

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: Morphine will be given to patients as part of their standard care

Intervention type: DRUG
Group type: OTHER
Intervention: Oxcarbazepine
Description: Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
Study: NCT02488148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hot yoga
Description: Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-heated yoga
Description: Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
Study: NCT03144830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton
Description: This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
Study: NCT02792283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: whole blood collection
Study: NCT03152188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fifteen FMT Openbiome capsules administered at the same time

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifteen placebo capsules administered at the same time
Study: NCT00693693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone 17-butyrate 0.1% Cream preparation
Description: Apply medication twice a day to affected areas of atopic dermatitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone 17-butyrate 0.1% Ointment preparation
Description: Apply medication twice a day to affected areas of atopic dermatitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone 17-butyrate 0.1% Lipocream preparation
Description: Apply medication twice a day to affected areas of atopic dermatitis
Study: NCT02541500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
Study: NCT04348188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program on healthy habits
Description: 6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program on healthy habits
Description: 6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
Study: NCT02163668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: 8 months of Yoga training
Study: NCT01807611

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: Participants receive total lymphoid irradiation over four doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV.
Study: NCT00277355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo 1 capsule twice daily, 18 months treatment duration.
Study: NCT00246805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitatron pacemaker C20 SSIR or T20 SSIR models
Description: VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
Study: NCT01807611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC,A Infusion
Description: Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TC-NK Infusion
Description: Participants receive infusions of TC-NK.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given intravenously or orally.
Study: NCT00683501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNB-001
Description: four dosages of DNB-001, one placebo dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNB-001
Description: four dosages of DNB-001, one placebo dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNB-001
Description: four dosages of DNB-001, one placebo dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNB-001
Description: four dosages of DNB-001, one placebo dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DNB-001
Description: four dosages of DNB-001, one placebo dosage